Research ExplorerPublicationsComparison of 10 Control hPSC Lines for Drug Screening in an...

Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format

Standard

Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. / Mannhardt, Ingra; Saleem, Umber; Mosqueira, Diogo; Loos, Malte F; Ulmer, Bärbel M; Lemoine, Marc D; Larsson, Camilla; Améen, Caroline; de Korte, Tessa; Vlaming, Maria L H; Harris, Kate; Clements, Peter; Denning, Chris; Hansen, Arne; Eschenhagen, Thomas.

In: STEM CELL REP, Vol. 15, No. 4, 13.10.2020, p. 983-998.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mannhardt, I, Saleem, U, Mosqueira, D, Loos, MF, Ulmer, BM, Lemoine, MD, Larsson, C, Améen, C, de Korte, T, Vlaming, MLH, Harris, K, Clements, P, Denning, C, Hansen, A & Eschenhagen, T 2020, 'Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format', STEM CELL REP, vol. 15, no. 4, pp. 983-998. https://doi.org/10.1016/j.stemcr.2020.09.002

APA

Mannhardt, I., Saleem, U., Mosqueira, D., Loos, M. F., Ulmer, B. M., Lemoine, M. D., Larsson, C., Améen, C., de Korte, T., Vlaming, M. L. H., Harris, K., Clements, P., Denning, C., Hansen, A., & Eschenhagen, T. (2020). Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. STEM CELL REP, 15(4), 983-998. https://doi.org/10.1016/j.stemcr.2020.09.002

Vancouver

Mannhardt I, Saleem U, Mosqueira D, Loos MF, Ulmer BM, Lemoine MD et al. Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. STEM CELL REP. 2020 Oct 13;15(4):983-998. https://doi.org/10.1016/j.stemcr.2020.09.002

Bibtex

@article{652deb49b24c48a2b6cd6a03989ba0d1,
title = "Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format",
abstract = "Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially available, and cardiac differentiation established routine. Systematic evaluation of several control hiPSC-CM is lacking. We investigated 10 different control hiPSC-CM lines and analyzed function and suitability for drug screening. Five commercial and 5 academic hPSC-CM lines were casted in engineered heart tissue (EHT) format. Spontaneous and stimulated EHT contractions were analyzed, and 7 inotropic indicator compounds investigated on 8 cell lines. Baseline contractile force, kinetics, and rate varied widely among the different lines (e.g., relaxation time range: 118-471 ms). In contrast, the qualitative correctness of responses to BayK-8644, nifedipine, EMD-57033, isoprenaline, and digoxin in terms of force and kinetics varied only between 80% and 93%. Large baseline differences between control cell lines support the request for isogenic controls in disease modeling. Variability appears less relevant for drug screening but needs to be considered, arguing for studies with more than one line.",
author = "Ingra Mannhardt and Umber Saleem and Diogo Mosqueira and Loos, {Malte F} and Ulmer, {B{\"a}rbel M} and Lemoine, {Marc D} and Camilla Larsson and Caroline Am{\'e}en and {de Korte}, Tessa and Vlaming, {Maria L H} and Kate Harris and Peter Clements and Chris Denning and Arne Hansen and Thomas Eschenhagen",
note = "Copyright {\textcopyright} 2020 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = oct,
day = "13",
doi = "10.1016/j.stemcr.2020.09.002",
language = "English",
volume = "15",
pages = "983--998",
journal = "STEM CELL REP",
issn = "2213-6711",
publisher = "Cell Press",
number = "4",

}

RIS

TY - JOUR

T1 - Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format

AU - Mannhardt, Ingra

AU - Saleem, Umber

AU - Mosqueira, Diogo

AU - Loos, Malte F

AU - Ulmer, Bärbel M

AU - Lemoine, Marc D

AU - Larsson, Camilla

AU - Améen, Caroline

AU - de Korte, Tessa

AU - Vlaming, Maria L H

AU - Harris, Kate

AU - Clements, Peter

AU - Denning, Chris

AU - Hansen, Arne

AU - Eschenhagen, Thomas

N1 - Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2020/10/13

Y1 - 2020/10/13

N2 - Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially available, and cardiac differentiation established routine. Systematic evaluation of several control hiPSC-CM is lacking. We investigated 10 different control hiPSC-CM lines and analyzed function and suitability for drug screening. Five commercial and 5 academic hPSC-CM lines were casted in engineered heart tissue (EHT) format. Spontaneous and stimulated EHT contractions were analyzed, and 7 inotropic indicator compounds investigated on 8 cell lines. Baseline contractile force, kinetics, and rate varied widely among the different lines (e.g., relaxation time range: 118-471 ms). In contrast, the qualitative correctness of responses to BayK-8644, nifedipine, EMD-57033, isoprenaline, and digoxin in terms of force and kinetics varied only between 80% and 93%. Large baseline differences between control cell lines support the request for isogenic controls in disease modeling. Variability appears less relevant for drug screening but needs to be considered, arguing for studies with more than one line.

AB - Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially available, and cardiac differentiation established routine. Systematic evaluation of several control hiPSC-CM is lacking. We investigated 10 different control hiPSC-CM lines and analyzed function and suitability for drug screening. Five commercial and 5 academic hPSC-CM lines were casted in engineered heart tissue (EHT) format. Spontaneous and stimulated EHT contractions were analyzed, and 7 inotropic indicator compounds investigated on 8 cell lines. Baseline contractile force, kinetics, and rate varied widely among the different lines (e.g., relaxation time range: 118-471 ms). In contrast, the qualitative correctness of responses to BayK-8644, nifedipine, EMD-57033, isoprenaline, and digoxin in terms of force and kinetics varied only between 80% and 93%. Large baseline differences between control cell lines support the request for isogenic controls in disease modeling. Variability appears less relevant for drug screening but needs to be considered, arguing for studies with more than one line.

U2 - 10.1016/j.stemcr.2020.09.002

DO - 10.1016/j.stemcr.2020.09.002

M3 - SCORING: Journal article

C2 - 33053362

VL - 15

SP - 983

EP - 998

JO - STEM CELL REP

JF - STEM CELL REP

SN - 2213-6711

IS - 4

ER -